- Efficacy of S-1 in colorectal cancer
Yuji Miyamoto et al, 2014, Expert Opinion on Pharmacotherapy CrossRef - Effect of CYP2A6 Genetic Polymorphism on the Metabolic Conversion of Tegafur to 5-Fluorouracil and Its Enantioselectivity
Ikuo Yamamiya et al, 2014, Drug Metabolism and Disposition CrossRef - Pharmacokinetics, Pharmacodynamics, and Toxicities: What Should We Know About Genetic Factors that Affect the Pharmacotherapy of Pulmonary Diseases?
Takashi Sato, 2018, Clinical Relevance of Genetic Factors in Pulmonary Diseases CrossRef - Emerging Pathophysiology and Treatment of Prostate Cancer: Future Perspective
Rahul Rawat et al, 2023, Handbook of Oncobiology: From Basic to Clinical Sciences CrossRef - Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies
Hiroto Matsui et al, 2018, Expert Review of Anticancer Therapy CrossRef - Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
Masakazu Toi et al, 2021, The Lancet Oncology CrossRef - PharmGKB summary
Ellen M. McDonagh et al, 2012, Pharmacogenetics and Genomics CrossRef - Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients
Lucía Cortejoso et al, 2012, Pharmacogenomics CrossRef - S-1 as a core anticancer fluoropyrimidine agent
Koh Miura et al, 2012, Expert Opinion on Drug Delivery CrossRef - Genotypes Affecting the Pharmacokinetics of Anticancer Drugs
Daphne Bertholee et al, 2017, Clinical Pharmacokinetics CrossRef - Variation in CYP2A6 Activity and Personalized Medicine
Julie-Anne Tanner et al, 2017, Journal of Personalized Medicine CrossRef - Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
Anthi Maslarinou et al, 2023, Frontiers in Pharmacology CrossRef - Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study
Eisuke Booka et al, 2016, Gastric Cancer CrossRef